SCHEMBL20589653

SCHEMBL20589653

Cc1ccc2c(N3CCCC3CO)nc(Cl)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACVR1 Q04771 3/20 0.51
▸ CCNE2 O96020 1/20 0.49
▸ CDK4 P11802 1/20 0.49
▸ CCND1 P24385 1/20 0.49
▸ CCNE1 P24864 1/20 0.49
▸ CDK2 P24941 1/20 0.49
▸ ADORA2A P29274 4/20 0.42
▸ ADORA1 P30542 4/20 0.42
▸ ADORA3 P0DMS8 3/20 0.42
▸ MAP2K7 O14733 1/20 0.41
▸ PDK2 Q15119 2/20 0.40
▸ PDK4 Q16654 1/20 0.40
▸ MAT2A P31153 1/20 0.40
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ CUL4A Q13619 1/20 0.37
▸ HRH4 Q9H3N8 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.37
▸ CNR2 P34972 2/20 0.36
▸ MKNK1 Q9BUB5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20589654 1.00 ACVR1 (0.51) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL20589380 0.86 CCNE2 (0.52) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL25214716 0.86 CCNE2 (0.49) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL25214718 0.86 CCNE2 (0.49) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL20589381 0.86 CCNE2 (0.52) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL20590008 0.83 CCNE2 (0.57) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL20589298 0.83 CCNE2 (0.47) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL28367306 0.83 CCNE2 (0.47) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL20590009 0.83 CCNE2 (0.57) ACVR1CCNE2CDK4CCND1CCNE1
SCHEMBL20589286 0.83 CCNE2 (0.69) ACVR1CCNE2CDK4CCND1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376117-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-11-14 — — US disclosed
US-12054492-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2024-08-06 — — US disclosed
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-08-31 — — US disclosed
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2023-05-30 — — US disclosed
US-20220332723-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2022-10-20 — — US disclosed
EP-3638229-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE Biocryst Pharmaceuticals, Inc. (US) 2020-04-22 — — EP disclosed
CN-110913855-A Imidazole-containing ALK2 kinase inhibitors 拜奥克里斯特制药公司 2020-03-24 — — CN disclosed
WO-2018232094-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE BIOCRYST PHARMACEUTICALS, INC. (US) 2018-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A ACVR1 4/4885CCNE2 3721/4885CDK4 508/4885
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase ALK, ACVR2B, ACVR2A ACVR1 4/4885CCNE2 3721/4885CDK4 508/4885
US-20240376117-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A ACVR1 4/4885CCNE2 3721/4885CDK4 508/4885
US-20220332723-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A ACVR1 4/4885CCNE2 3721/4885CDK4 508/4885
US-12054492-B2 Imidazole-containing inhibitors of ALK2 kinase ALK, ACVR2B, ACVR2A ACVR1 4/4885CCNE2 3721/4885CDK4 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback